Abstracts tagged "Animal models"

Abstract Number: 337 • 2014 ACR/ARHP Annual Meeting
Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis
Perle Totoson¹, Katy Maguin-Gaté¹, Daniel Wendling² and Céline Demougeot¹, ¹EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose Growing evidence indicate that Rheumatoid Arthritis (RA)-associated increase in cardiovascular risk is secondary to the presence of endothelial dysfunction (ED). Although Tumor Necrosis Factor…
Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting
The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice
Jennifer L. Auger¹, Brianna J. Engelson², Yaya Wang³, Erik J. Peterson⁴ and Bryce A. Binstadt⁵, ¹Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ²Pediatrics, University of Minnesota, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
Abstract Number: 1706 • 2014 ACR/ARHP Annual Meeting
Prevention of SU5416-Induced Pulmonary Hypertension in a TGFβ Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan
Emma C. Derrett-Smith¹, Vincent Sobanski², Sarah Trinder³, Adrian J Gilbane³, Marc Iglarz⁴, David J. Abraham³, Alan M. Holmes⁵ and Christopher P Denton⁶, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ²UCL Medical School, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases. We have previously shown that…
Abstract Number: 744 • 2014 ACR/ARHP Annual Meeting
Integrin Inhibitor Modulates Pulmonary Fibrosis in the Reactive Oxygen Species Murine Model of Systemic Sclerosis
Gianluca Bagnato¹, Alessandra Bitto², Natasha Irrera², Gabriele Pizzino², Neal Roberts³, Domenica Altavilla², Francesco Squadrito², Antonino Saitta⁴ and Gianfilippo Bagnato⁵, ¹Rheumatology, University of Messina, Messina, Italy, ²Pharmacology, University of Messina, Messina, Italy, ³University of Louisville, Louisville, KY, ⁴Internal Medicine, University of Messina, Messina, Italy, ⁵Via C. Colombo, 41, Universita Messina, Villafranca Tirrena, Italy
Background/Purpose: Systemic sclerosis (SSc) is an acquired connective tissue disorder in which inflammation, immune dysregulation and vascular damage lead to fibroblast activation that results in…
Abstract Number: 336 • 2014 ACR/ARHP Annual Meeting
The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit
M.R. Hillen^1,2, S.A.Y. Hartgring^1,2, T.R.D.J. Radstake^2,3, C.E. Hack^1,2, F.P.J.G. Lafeber¹ and J.a.G. van Roon^1,2, ¹Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Interleukin (IL)-7 and thymic stromal lymphopoietin (TSLP) are cytokines that signal through the IL-7Ra subunit and play proinflammatory roles in experimental arthritis and rheumatoid…
Abstract Number: 2878 • 2014 ACR/ARHP Annual Meeting
G Protein Signaling Modulator 3 (GPSM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GPSM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans
Teresa K. Tarrant¹, D. Stephen Serafin², Elizabeth Sugg², Roman Timoshchenko², Matthew J. Billard², David P. Siderovski³ and Kristy Richards⁴, ¹Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Physiology and Pharmacology, West Virginia University School of Medicine, Morgantown, WV, ⁴Medicine, Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose GPSM3, a newly described regulator of heterotrimeric G protein signaling, is selectively expressed in hematopoietic cells with high expression in monocytes. We have shown…
Abstract Number: 1718 • 2014 ACR/ARHP Annual Meeting
B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis
Sébastien Sanges^1,2,3, Niloufar Kavian⁴, Carine Hauspie^1,3,5, Carole Nicco⁴, Thomas Guerrier^1,3, Virginie Dutoit-Lefèvre^1,3, Guillaume Lefèvre^1,2,5,6, Alexandra Forestier^1,2,3, Vincent Sobanski^1,2,6, Christelle Faveeuw⁷, Myriam Labalette^1,3,5, Frédéric Batteux⁴, David Launay^1,2,3 and Sylvain Dubucquoi^1,3,5, ¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³EA 2686, Lille, Lille, France, ⁴Université Paris Descartes, EA 1833, Hôpital Cochin, AP-HP, Paris, Paris, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶EA 2686, Lille, LILLE, France, ⁷Institut National de la Santé et de la Recherche Médicale Unité 547, Institut Pasteur de Lille, Institut Fédératif de Recherche 142, Université de Lille Nord de France, Lille, France
Background/Purpose Systemic sclerosis (SSc) is a multi-organ fibrotic disease associated with auto-immune abnormalities. Several clinical and experimental observations suggest that B cells are involved in…
Abstract Number: 756 • 2014 ACR/ARHP Annual Meeting
Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells
Ayumi Yoshizaki¹, Yoshihide Asano², Takashi Taniguchi¹, Ryosuke Saigusa¹, Kouki Nakamura¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Zenshiro Tamaki¹, Miki Miyazaki¹ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose Nucleosome is the basic repeating units of chromatin. Each nucleosome is composed of an inner core of histones H3 and H4 and an outer…
Abstract Number: 20 • 2014 ACR/ARHP Annual Meeting
High Systemic LDL Cholesterol Levels during Experimental Osteoarthritis Lead to Increased Synovial Activation and Ectopic Bone Formation at End-Stage Osteoarthritis, While Excessive Levels Accelerate Development of Joint Pathology Already at Early-Stage Osteoarthritis
Wouter de Munter, Martijn H. van den Bosch, Annet W. Sloetjes, Peter M. van der Kraan, Wim B. van den Berg and Peter L. van Lent, Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: A relation between osteoarthritis (OA) and the metabolic syndrome has long been established. One of the characteristics of the metabolic syndrome is increased cholesterol…
Abstract Number: 2863 • 2014 ACR/ARHP Annual Meeting
IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study
Charis Pericleous¹, Valerie Taylor², Lauren Bourke³, Daniel Stuckey², Jed Wingrove⁴, Mark Lythgoe⁵, Silvia S. Pierangeli⁶, Anisur Rahman³, Ian Giles¹ and Yiannis Ioannou⁷, ¹Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Centre for Advanced Biomedical Imaging, University College London, London, United Kingdom, ⁵Centre for Advanced Biomedical Imaging, Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, ⁶Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁷Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose Circulating pathogenic antiphospholipid antibodies (aPL) are the hallmark of antiphospholipid syndrome (APS) and a major risk factor for ischemic stroke, with up to one…
Abstract Number: 1495 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
Gene Marcantonio¹, Alan Bass², Gretchen Baltus³, Judith Boice¹, Hongmin Chen⁴, Michael Crackower⁵, Jeroen Elassaiss-Schaap⁶, Michael Ellis⁷, Tomoko Freshwater⁸, Francois Gervais⁹, Jane Guo¹⁰, Sammy Kim⁹, Lily Moy⁵, Alan Northrup⁷, Jie Zhang-Hoover⁴, Mathew Maddess¹¹, Richard Miller¹², Marcella Ruddy⁵, Stella Vincent¹³, Haoling Weng¹ and Hani Houshyar¹⁴, ¹Merck & Co., Whitehouse Station, NJ, ²Safety Assessment, Merck & Co., Boston, MA, ³Immunomodulatory Regulators, Merck & Co., Boston, MA, ⁴Pharmacology, Merck & Co., Boston, MA, ⁵Merck & Co., Boston, MA, ⁶Clinical PK-PD, Merck & Co., Oss, Netherlands, ⁷Medicinal Chemistry, Merck & Co., Boston, MA, ⁸PPDM Early Stage, Merck & Co., Rahway, NJ, ⁹Cell Pathways and Proteins, Merck & Co., Boston, MA, ¹⁰Immunology, Merck & Co., Boston, MA, ¹¹Discovery Process Chemistry, Merck & Co., Boston, MA, ¹²Biochemistry & Biophysics, Merck & Co., Boston, MA, ¹³PPDM Preclinical ADME, Merck & Co., Boston, MA, ¹⁴33 Avenue Louis Pasteur, Merck & Co., Boston, MA
Background/Purpose: Spleen tyrosine kinase (SYK) is a potential target for treatment of several diseases including rheumatoid arthritis. SYK is a member of the Zeta-chain-associated protein…
Abstract Number: 660 • 2014 ACR/ARHP Annual Meeting
Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis
María Galindo¹, Elena Gonzalo-Gil², Oscar Toldos³, Carmen García-Herrero², Alicia Usategui¹, Sonia Pérez-Yagüe⁴, Gabriel Criado⁵, Domingo F. Barber⁴ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Servicio de Anatomia Patologica, Hospital 12 de Octubre, Madrid, Spain, ⁴Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies.…
Abstract Number: 2796 • 2014 ACR/ARHP Annual Meeting
A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes
Xian-Peng Ge¹, Susan Y. Ritter², Julia F. Charles³, Kelly Tsang² and Antonios O. Aliprantis², ¹Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Osteochondromas are the most common benign bone tumor and are characterized by cartilage-capped bony projections from the external surface of bone. These lesions may…
Abstract Number: 1036 • 2014 ACR/ARHP Annual Meeting
Synergism Between GM-CSF and IL-17 Causes Enhanced Joint Pathology Via the Production of IL-6 and IL-23
Annemarie E.M. van Nieuwenhuijze¹, Debbie M. Roeleveld², Birgitte Walgreen², Miranda Bennink¹, Monique M. Helsen¹, Liduine van den Bersselaar¹, Ian P. Wicks³, Wim B. van den Berg¹, Fons A. van de Loo¹ and Marije I. Koenders¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimentel Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
Abstract Number: 656 • 2014 ACR/ARHP Annual Meeting
Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice
Kieran Manion^1,2, Nan-Hua Chang³, Yuriy Baglaenko^1,2 and Joan Wither^1,3, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, ³Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mapping studies in the lupus-prone New Zealand Black (NZB) mouse strain identified an interval from 170.8-181 Mb on chromosome 1 sufficient to induce B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].